A EULAR 2022 abstract session looked at several studies that seek to increase understanding of RA pathogenesis & identify patients at risk for disease progression.
Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis
Dr. Jacob van Laar took a deep dive into the what defines difficult-to-treat rheumatoid arthritis & how to approach these patients during EULAR 2022.
Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More
In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.
FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA
Based on findings from a double-blind, placebo-controlled study evaluating its efficacy and safety, rituximab-arrx has received FDA approval for the treatment of patients with rheumatoid arthritis.
Gene Profiling May Predict Treatment Response in Refractory Rheumatoid Arthritis
NEW YORK (Reuters Health)—In patients with rheumatoid arthritis (RA) refractory to treatment with rituximab or tocilizumab, genetic profiling of synovial biopsies predicted the lack of therapeutic response better than a model using only tissue pathology or clinical factors, researchers say.1 “We believe this study is a paradigm shift in precision medicine in RA,” Dr. Costantino…
Researchers Should Use ACR/EULAR Definition of RA Remission in Clinical Studies
Clinical trials in rheumatoid arthritis (RA) should use the new ACR/EULAR remission definition rather than the Disease Activity Score-28-CRP, which does not sufficiently reflect patient outcomes, according to an ACR/EULAR committee.
Remission Definitions in RA: Common Questions & Implications for Clinical Practice
A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.
DNA Methylation Profiles May Shed Light on the Evolution of Arthritis in Patients
A study found DNA methylation profiling may predict if a patient will progress from a diagnosis of undifferentiated arthritis to that of rheumatoid arthritis (RA). The findings also suggest a pre-established epigenetic signature exists in patients diagnosed with undifferentiated arthritis that evolves into RA.
The Power of Power Doppler: Ultrasound Imaging in RA
At the 17th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases meeting, Dana DiRenzo, MD, MHS, RhMSUS, discussed the use of ultrasound imaging in patients with inflammatory arthritis.
Tissue Evaluation: Understanding Rheumatoid Arthritis Inside & Out
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Clifton Bingham, MD, delves into research into rheumatoid arthritis at the cellular level.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 30
- Next Page »